https://orcid.org/0000-0003-3484-7536
Figures
Abstract
Introduction
The Platelet Function Analyzer-100 (PFA-100) is a point of care instrument that simulates plug formation under high shear flow. The PFA-100 measures the time required to occlude the aperture in a biochemically active cartridge and is expressed in a term of closure time (CT). In Algeria, the reference values used in clinical laboratories are of Western origin. However, ethnic, genetic, dietary environmental, and diet differences between populations may affect reference intervals. We established the reference intervals of PFA-100 closure times in healthy Algerian adults according to the International Federation of Clinical Chemistry method, and we compared them with those of Western and Asian countries.
Material and methods
We enrolled 303 healthy blood donors in the study. 218 subjects met inclusion criteria. We analyzed the blood sample on the PFA-100 for CT with both the collagen epinephrine and collagen ADP cartridges.
Results
The reference intervals of PFA-100 collagen epinephrine CT and PFA-100 collagen ADP CT were 91–207 seconds and 71–144 seconds, respectively. Compared to Western and Asian populations, there were significant differences. The upper limits of CTs were higher for Algerians in this study. Our findings show that many healthy Algerians would be incorrectly identified as having a primary hemostasis abnormality according to the reference intervals of the manufacturer and scientific literature.
Citation: Belkacemi M, Merad Y, Merbouh MA (2021) Establishment of reference intervals for Platelet Function Analyzer -100 closure time in Algerian adults. PLoS ONE 16(4): e0249402. https://doi.org/10.1371/journal.pone.0249402
Editor: Elizabeth S. Mayne, University of Witwatersrand/NHLS, SOUTH AFRICA
Received: July 9, 2020; Accepted: March 17, 2021; Published: April 12, 2021
Copyright: © 2021 Belkacemi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting Information files.
Funding: The auteurs received no specific funding of this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The PFA-100 is a point of care instrument for hemostasis testing. Citrated whole blood passes at high shear rates through disposable cartridges containing an aperture in a membrane coated with Collagen and Epinephrine (CEPI) or Collagen and ADP (CADP) [1]. These agonists, with the high shear stress, induce a plug formation in and around the aperture. The time required to occlude the aperture and to stop blood flow is called the closure time (CT). The PFA-100 is an automated alternative to the bleeding time (BT) test, which is no longer recommended [2]. The PFA-100 allows rapid and global evaluations of primary hemostasis. Recently, we equipped our laboratory with this instrument. However, there are few studies on the reference intervals (RIs) for PFA-100 CTs. In addition, most of the studies do not meet international recommendations such as defined in the International Federation of Clinical Chemistry (IFCC) and Clinical and Laboratory Standards Institute (CLSI) guidelines. All the previous studies were conducted in the Western or Asian populations. In Algeria, clinical laboratories use the reference intervals (RIs) of PFA-100 provided by manufacturers which are of Western origin. We know that ethnic, genetic, and dietary differences between populations may affect RIs. So far, we have not come across any literature on Algerian reference values for PFA-100 CT. To respond to this lack, we decided to determine the RIs of the PFA-100 CT in healthy Algerian adults. We then compared the findings with those available in the Western and Asian healthy populations.
Material and methods
Selection of healthy subjects and study design
This prospective study was conducted at the blood transfusion department of the Sidi Bel Abbes City. The choice of donors is founded on the possibility that the population is supposedly in good health and that it receives a medical selection. The doctor who allows or prohibits the donation completes an information sheet. It includes personal information such as sex and age, a history of allergy, viral, bacterial or parasitic infectious disease, stays abroad, transfusion, surgery, medication or vaccination. Consent was obtained for all participants. We included in our study any Algerian adult male and female able to donate after the medical consultation. The criteria for inclusion and non-inclusion are those of blood donors. Exclusion criteria are positive HIV serology, positive HCV serology, positive HBS Ag serology, positive syphilis serology, taking aspirin or a nonsteroidal anti-inflammatory drug (NSAID), antibiotic or other drugs with a potential to influence platelet function within ten days before collection, platelet count below 150G / L or hematocrit less than 0.35 or a von Willebrand factor Antigen (vWF Ag) < 50%. The study was approved by the local ethics committee of the Hospital University Center of Sidi Bel Abbes. A minimum of 120 subjects is recommended by CLSI to establish Reference interval values [3]. 303 healthy adult (≥18 years old) were recruited. Among them, 85 were excluded: 56 for the use of aspirin or an NSAID, 14 due to hematocrit less than 0.35 and 15 because of a platelet count below 150G / L. Thus, a total of 218 subjects were included in our analysis.
Specimen collection and processing
Blood samples were drawn from each subject at the beginning of the donation. Whole blood was collected into EDTA collection tubes for complete blood counts (CBC) determination. Blood for PFA-100 testing and routine hemostatic testing was drawn into 0.129 mol/l (3.8%) sodium citrate collection tubes. Samples for PFA-100 testing were stored at room temperature before testing. Hemolyzed or clotted samples were not used. All the samples were obtained in the morning (between 8:30 and 11:00 am). Platelet poor plasma (PPP) was obtained by centrifugation at 3500 x g for 10 min. Aliquots of 0,5 ml of PPP were snap-frozen and stored at -80C. When required for further analysis vWF: Ag samples were thawed at 37°C for 10 min.
Assay
PFA-100 CT.
CEPI CT and CADP CT were determined between 30 min and 1 h after blood collection, using one single lot each of CEPI and CADP cartridges by PFA-100 TM instrument from Siemens Health Diagnostics (Marburg, Germany).
CBC.
The CBC was performed on the Sysmex XT-2000i Automated Hematology Analyzer From Sysmex Corporation, Kobe, Japan.
Data analysis
The distribution of each variable was first inspected visually to check for normality and possible outliers. The latter were tested by Dixon’s criterion. The D’Agostino-Pearson test for normality was used to analyze the values. As not all values were normally distributed, data were presented as either median and range or as mean ± standard deviation (SD). Paired and unpaired data were compared using the Wilcoxon test and the U Whitney test, respectively. The t-test was used to compare the mean between the groups. Differences in frequencies were checked by the Chi-square test.
RIs was determined by the nonparametric method according to the IFCC and CLSI recommendations. It is based on the 2.5th and 97.5th percentile rankings and the calculation of their 90% confidence interval (CI) [4].
The RIs obtained in this study was compared to that provided by the manufacturer and other foreign studies by checking the number of our subjects who fell outside the predefined upper limit value. Differences found in proportions found were checked by Fisher’s exact test.
Statistical analyses were performed using Statistical Package for Social Science SPSS version 25 (IBM SPSS Armonk NY, USA) and, MedCalc Statistical Software version 15, 0 (MedCalc Software, Ostend, Belgium). The p value <0.05 was considered statistically significant.
Results
Characteristics of the reference sample
218 healthy Algerian adults (>18 years old) were enrolled in this study. Baseline data for all individuals, men and women are shown in Table 1. Females and males did not differ in age or the proportion of blood group O. Concerning smoking behaviour, as expected; the proportion of female smokers was significantly lower than that of male smokers. The distribution of subjects according to the ABO blood group was: 44% are of group O, 31% of group A, 19.8% of group B and 5.2% are of group AB. The frequency of phenotypes O, A, B, AB in the population of western Algeria is respectively 42.7%, 32.1%, 19.3%, 5.9%and therefore there was no significant difference between our sample and the population from west Algeria [5].
Reference intervals
The distributions of the CEPI CT and CADP CT values differed significantly from the Gaussian curve (p< 0,001). After an evaluation of the data by the Dixon test, there were no outliers. The results of the statistical analysis of CEPI CT and CADP CT are shown in Table 2. The RIs of the CEPI CT and CADP CT determined by the 95% Central Interval and 90% CI for upper and lower limit calculated by the two methods (parametric and non-parametric) Table 3. The Figs 1 and 2 illustrate the RIs respectively for CEPI and CADP CT PFA100 determined by the non-parametric method.
Comparison of the local interval with that of the manufacturer and the foreign populations
As observed in Table 4, similar studies were conducted in Western and Asian populations [6–11]. The RIs provided by the manufacturer of CEPI CT and CADP CT in 3.8% buffered citrate are respectively [84–160] sec and [68–121] sec established on 127 healthy adults. In our comparative study of the RIs, we showed the proportions of our subjects which are classified by the RIs of the manufacturer and other foreign studies as having an abnormality of primary hemostasis in Table 5.
Discussion
We designed this prospective study according to IFCC–CLSI guidelines for the de novo establishment of RIs of the PFA-100 CT in Algerian adults after standardization of the preanalytical variables. The strength of the present study is the sample size. To our knowledge, this report is the first to determine the RIs of PFA-100 CT in Algeria. Clinical laboratories can validate the local RIs depending on local conditions. The results of our survey show that the local RIs differ from Western and Asian populations. The upper limits for CTs were higher in our study. Using the RIs of the foreign population shows that many healthy Algerian adults could be incorrectly identified as having primary hemostatic defect. Hence, the RIs determined for another population are inappropriate for our population. The ethnic, genetic, dietary and environmental factors influence the pathophysiology of hemostasis and thrombosis [12–14]. Variations in the studies’ methods reported would also lead to different RIs [6–11]. Furthermore, the high prevalence of blood group O among African may also explain the difference RIs between populations [15]. Individuals with blood group O have longer PFA-100 CT [16]. The PFA-100 CT strongly depends on the vWF plasma level, which is lower in blood group O than in other blood groups [17, 18]. Under high shear stress, vWF acts as the mediator for both platelet adhesion and aggregation [19]. Lower levels of vWF affect the formation of a hemostatic plug and typically prolong PFA-100 CT [20]. Our result confirms the influence of ABO blood group on PFA-100 CT. Therefore, it would be more suitable to use these results rather than the RIs from foreign countries to eliminate the variability between local laboratories. It is obvious from this study that there was a need to establish site-specific RIs PFA-100 CT applicable to our population.
Conclusion
The RIs provided by the kit manufacturers and scientific literature are foreign to the local population. Therefore, the determination of RIs for CT PFA-100 in the local laboratory has an irreplaceable role for further use of PFA-100 in everyday clinical practice. This report is the first to determine the RIs of PFA-100 CT in a well-characterized healthy Algerian population. Thus, other Algerian clinical laboratories could adopt local RIs after verification or validation. These improve the accuracy of diagnosis and patient care in Algeria.
Supporting information
S1 Table. Data collection of 218 healthy individuals.
https://doi.org/10.1371/journal.pone.0249402.s001
(XLSX)
Acknowledgments
We would like to thank all the staff of the blood transfusion department of Sidi-Bel-Abbes city
References
- 1. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006; 4(2): 312–9. pmid:16420557
- 2. Franchini M. The platelet-function analyzer (PFA-100) for evaluating primary hemostasis. Hematology. 2005; 10(3): 177–81. pmid:16019466
- 3. Solberg HE. The IFCC recommendation on estimation of reference intervals. The RefVal program. Clin Chem Lab Med. 2004; 42(7): 710–4. pmid:15327004
- 4. Boyd J. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guidelines. CLSI document C28–A3; 2010
- 5. Zaoui S, Feingold J, Meguenni K, Chabane Sari D. ABO and rhesus blood groups system in Tlemcen population. West Algerian. BES. 2007; 7(1): 62–71
- 6. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost.1998; 24(2): 195–202. pmid:9579642
- 7. Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS. et al. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost. 2000; 84(1): 93–7. pmid:10928477
- 8. Böck M, De Haan J, Beck KH, Gutensohn K, Hertfelder HJ, Karger R, et al. Standardization of the PFA-100® platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol. 1999; 106(4): 898–904. pmid:10519990
- 9. Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert UT, Hellstern P, et al. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. Br J Haematol. 2005; 130(5): 759–67. pmid:16115134
- 10. Korinkova L, Stasko J, Kubisz P, Grendar M. Variables That Affect Results of PFA-100 in a Group of Healthy Blood Donors in the Slovak Population. Acta Medica Martiniana, 2017. 17.
- 11. Cho YU, Jang S, Park CJ, Chi HS. Variables that affect platelet function analyzer-100 (PFA-100) closure times and establishment of reference intervals in Korean adults. Ann Clin Lab Sci. 2008; 38(3): 247–53. pmid:18715853
- 12. White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res. 2009; 123 Suppl 4:S11–7. pmid:19303496
- 13. McEwen BJ. The influence of diet and nutrients on platelet function. Semin Thromb Hemost. 2014; 40(2): 214–26. pmid:24497119
- 14. Crous-Bou M, Harrington LB, Kabrhel C. Environmental and genetic risk factors associated with venous thromboembolism. Semin Thromb Hemost. 2016; 42(8): 808–20. pmid:27764878; PMCID: PMC5146955
- 15. Dewan G. Comparative frequency and allelic distribution of ABO and Rh (D) blood groups of major tribal communities of southern Bangladesh with general population and their determinants. Egyptian Journal of Medical Human Genetics. 2015;16(2): 141–147.
- 16. Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost. 2001; 85(2):369–70. pmid:11246563.
- 17. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost, 2008. 34(8): 709–33. pmid:19214910
- 18. Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J. 2007; 5(14). PMCID: PMC2042969 pmid:17894864
- 19. Jackson SP. The growing complexity of platelet aggregation. Blood. 2007; 109(12): 5087–95. pmid:17311994
- 20. Lasne D, Fiemeyer A, Chatellier G, Chammas C, Baron JF, Aiach M. A study of platelet functions with a new analyzer using high shear stress (PFA 100) in patients undergoing coronary artery bypass graft. Thromb Haemost. 2000; 84(5): 794–9. pmid:11127858.